The medical and functional burden of surviving childhood ependymoma: A population‐based study in Ontario, Canada

Hallie Coltin,Priscila Pequeno,Ning Liu,Derek S. Tsang,Sumit Gupta,Michael D. Taylor,Eric Bouffet,Vijay Ramaswamy,Paul C. Nathan
DOI: https://doi.org/10.1002/pbc.31275
2024-08-18
Pediatric Blood & Cancer
Abstract:Background Few studies have characterized the burden of late effects among childhood ependymoma survivors. To address this gap, we examined these sequelae using real‐world health services data in a population‐based ependymoma survivor cohort. Methods All individuals younger than 18 years diagnosed with an ependymoma in Ontario, Canada between 1987 and 2015 who had survived at least 5 years from their latest pediatric cancer event (index date) were matched 1:5 with population controls. Following linkage with provincial health services data, the cumulative incidences of multiple medical and functional outcomes between survivors and controls were compared. Results Among 96 survivors, 77.1% had been irradiated and 9.4% had received cisplatin. At 10 years post‐index, survivors were at significantly higher risk of all‐cause mortality (7.1%, 95% confidence interval [CI]: 1.0–13.3 vs. 0.3%, 95% CI: 0.0–1.0; p = .0002), non‐obstetric hospitalization (45.1%, 95% CI: 32.6–56.7 vs. 10.6%, 95% CI: 7.6–14.1; p
oncology,pediatrics,hematology
What problem does this paper attempt to address?